Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration

1. A method for reducing or preventing the formation of high molecular weight protein aggregates of a bispecific antibody construct in a pharmaceutical composition, the method comprising providing a pharmaceutical composition comprising

i) a bispecific antibody construct, wherein the construct binds to a target cell surface antigen via a first binding domain and to the T cell surface antigen CD3 via a second binding domain, wherein the bispecific antibody construct is present in a concentration in the range from 0.5 μg/ml to 20 mg/ml;

ii) benzyl alcohol in a concentration in the range from 0.11 to 0.9% (w/v), and

iii) a buffer comprising a salt selected from the group consisting of phosphate, acetate, citrate, succinate and tartrate, or wherein the buffer comprises histidine, glycine, TRIS glycine, Tris, or mixtures thereof,

wherein the benzyl alcohol serves to physically and microbiologically stabilize the pharmaceutical composition during storage and administration,

wherein the bispecific antibody construct shows reduction or prevention of the formation of protein aggregates (high molecular weight (HMW) species), and wherein the percentile HMW concentration is below 5%, and

wherein the composition is stored until use as a solution in a frozen state or as a lyophilisate and is then administered, after dilution or reconstitution, without requiring additional benzyl alcohol for dilution or reconstitution.

2. The method of claim 1 , wherein the bispecific antibody construct is present at a concentration in a range selected from the group consisting of:

(a) 0.5 to 200 μg/ml at a pH of 6.5 to 7.5,

(b) 0.5 to 1000 μg/ml at a pH of 4.0 to 6.0,

(c) 0.5 μg to 2 mg in the presence of a CD3 binding domain stabilizing agent, and

(d) 0.5 μg to 20 mg, at a pH of 4.0 to 7.5,

wherein the bispecific antibody comprises a third binding domain which comprises two polypeptide monomers, each comprising a hinge, a CH2 and a CH3 domain, wherein said two polypeptide monomers are fused to each other via a peptide linker, and wherein said third binding domain comprises in an amino to carboxyl order:

hinge-CH2-CH3-linker-hinge-CH2-CH3.

3. The method of claim 1 , wherein the bispecific antibody construct is a bispecific single chain antibody construct.

4. The method of claim 1 , wherein the buffer is selected from the group consisting of: potassium phosphate, acetic acid/sodium acetate, citric acid/sodium citrate, succinic acid/sodium succinate, tartaric acid/sodium tartrate, and histidine/histidine HCl or mixtures thereof.

5. The method of claim 1 , wherein the buffer is present at a concentration in a range from 0.1 to 150 mM.

6. The method of claim 1 , wherein the buffer comprises citrate.

7. The method of claim 6 , wherein the citrate is present at a concentration in a range from 0.25 to 50 mM.

8. The method of claim 1 , wherein the pH of the composition is in a range from 4.0 to 8.0.

9. The method of claim 1 , wherein the composition further comprises one or more excipients selected from the group consisting of: sucrose, trehalose, mannitol, sorbitol, arginine, lysine, polysorbate 20, polysorbate 80, poloxamer 188, and pluronic, and combinations thereof.

10. The method of claim 9 , wherein the composition further comprises polysorbate and/or lysine HCL, or wherein the composition does not further comprise polysorbate and/or lysine HCL if the concentration of the bispecific antibody construct is at least 10 μg/ml.

11. The method of claim 1 , wherein the first binding domain of the bispecific antibody construct binds to at least one target cell surface antigen selected from the group consisting of: CD19, CD33, EGFRvIII, MSLN, CDH19, FLT3, DLL3, CDH3, BCMA and PSMA.

12. The method of claim 1 , wherein the first binding domain comprises a VH region and a VL region comprising CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 selected from the group consisting of:

(a) CDR-H1 as set forth in SEQ ID NO: 1, CDR-H2 as set forth in SEQ ID NO: 2, CDR-H3 as set forth in SEQ ID NO: 3, CDR-L1 as set forth in SEQ ID NO: 4, CDR-L2 as set forth in SEQ ID NO: 5 and CDR-L3 as set forth in SEQ ID NO: 6;

(b) CDR-H1 as set forth in SEQ ID NO: 29, CDR-H2 as set forth in SEQ ID NO: 30, CDR-H3 as set forth in SEQ ID NO: 31, CDR-L1 as set forth in SEQ ID NO: 34, CDR-L2 as set forth in SEQ ID NO: 35 and CDR-L3 as set forth in SEQ ID NO: 36;

(c) CDR-H1 as set forth in SEQ ID NO: 42, CDR-H2 as set forth in SEQ ID NO: 43, CDR-H3 as set forth set forth in SEQ ID NO: 44, CDR-L1 as set forth in SEQ ID NO: 45, CDR-L2 as set forth in SEQ ID NO: 46 and CDR-L3 as set forth in SEQ ID NO: 47;

(d) CDR-H1 as set forth in SEQ ID NO: 53, CDR-H2 as set forth in SEQ ID NO: 54, CDR-H3 as set forth in SEQ ID NO: 55, CDR-L1 as set forth in SEQ ID NO: 56, CDR-L2 as set forth in SEQ ID NO: 57 and CDR-L3 as set forth in SEQ ID NO: 58;

(e) CDR-H1 as set forth in SEQ ID NO: 65, CDR-H2 as set forth in SEQ ID NO: 66, CDR-H3 as set forth in SEQ ID NO: 67, CDR-L1 as set forth in SEQ ID NO: 68, CDR-L2 as set forth in SEQ ID NO: 69 and CDR-L3 as set forth in SEQ ID NO: 70;

(f) CDR-H1 as set forth in SEQ ID NO: 83, CDR-H2 as set forth in SEQ ID NO: 84, CDR-H3 as set forth in SEQ ID NO: 85, CDR-L1 as set forth in SEQ ID NO: 86, CDR-L2 as set forth in SEQ ID NO: 87 and CDR-L3 as set forth in SEQ ID NO: 88;

(g) CDR-H1 as set forth in SEQ ID NO: 94, CDR-H2 as set forth in SEQ ID NO: 95, CDR-H3 as set forth in SEQ ID NO: 96, CDR-L1 as set forth in SEQ ID NO: 97, CDR-L2 as set forth in SEQ ID NO: 98 and CDR-L3 as set forth in SEQ ID NO: 99;

(h) CDR-H1 as set forth in SEQ ID NO: 105, CDR-H2 as set forth in SEQ ID NO: 106, CDR-H3 as set forth in SEQ ID NO: 107, CDR-L1 as set forth in SEQ ID NO: 109, CDR-L2 as set forth in SEQ ID NO: 110 and CDR-L3 as set forth in SEQ ID NO: 111;

(i) CDR-H1 as set forth in SEQ ID NO: 115, CDR-H2 as set forth in SEQ ID NO: 116, CDR-H3 as set forth in SEQ ID NO: 117, CDR-L1 as set forth in SEQ ID NO: 118, CDR-L2 as set forth in SEQ ID NO: 119 and CDR-L3 as set forth in SEQ ID NO: 120;

(j) CDR-H1 as set forth in SEQ ID NO: 126, CDR-H2 as set forth in SEQ ID NO: 127, CDR-H3 as set forth in SEQ ID NO: 128, CDR-L1 as set forth in SEQ ID NO: 129, CDR-L2 as set forth in SEQ ID NO: 130 and CDR-L3 as set forth in SEQ ID NO: 131;

(k) CDR-H1 as set forth in SEQ ID NO: 137, CDR-H2 as set forth in SEQ ID NO: 138, CDR-H3 as set forth in SEQ ID NO: 139, CDR-L1 as set forth in SEQ ID NO: 140, CDR-L2 as set forth in SEQ ID NO: 141 and CDR-L3 as set forth in SEQ ID NO: 142;

(l) CDR-H1 as set forth in SEQ ID NO: 152, CDR-H2 as set forth in SEQ ID NO: 153, CDR-H3 as set forth in SEQ ID NO: 154, CDR-L1 as set forth in SEQ ID NO: 155, CDR-L2 as set forth in SEQ ID NO: 156 and CDR-L3 as set forth in SEQ ID NO: 157; and

(m) CDR-H1 as set forth in SEQ ID NO: 167, CDR-H2 as set forth in SEQ ID NO: 168, CDR-H3 as set forth in SEQ ID NO: 169, CDR-L1 as set forth in SEQ ID NO: 170, CDR-L2 as set forth in SEQ ID NO: 171 and CDR-L3 as set forth in SEQ ID NO: 172.

13. The method of claim 1 , wherein the composition is liquid.

14. The method of claim 1 , wherein the multimers are dimers.

15. The method of claim 13 , wherein the composition comprises less than 5% of multimers of the bispecific antibody construct for a time period of at least 4 days at room temperature.

16. The method of claim 1 , wherein the composition is suitable for storage at −50° C., −40° C., −30° C., or −20° C.

17. The method of claim 16 ,

wherein the composition comprises the bispecific antibody comprising a third binding domain which comprises two polypeptide monomers, each comprising a hinge, a CH2 and a CH3 domain,

wherein said two polypeptide monomers are fused to each other via a peptide linker, and

wherein said third binding domain comprises in an amino to carboxyl order:

hinge-CH2-CH3-linker-hinge-CH2-CH3.

18. The method of claim 1 , wherein the composition is provided as a lyophilisate for storage.